204514-28-3

Upstream product

• 223763-92-6 tert-butyl [(1-(hydroxymethyl)cyclohexyl)methyl]carbamate 
• 204514-23-8 1-(<<(tert-butoxy)carbonyl>amino>methyl)cyclohexane-1-carboxylic acid 
• 2041-57-8 (1-(aminomethyl)cyclohexyl)methanol 
• 1130-21-8 ethyl 1-cyanocyclohexane-1-carboxylate 
• 111-24-0 1,5-dibromo-pentane 
• 204514-17-0 1-(tert-butoxycarbonylamino-methyl)-cyclohexanecarboxylic acid 1-allyloxycarbonyl-3-methyl-butyl ester 

Downstream Products

• 223764-02-1 (E)-(9S,12S,18R)-12-((1R,2R,3S)-3-Chloro-2-hydroxy-1-methyl-3-phenyl-propyl)-18-(3-chloro-4-methoxy-benzyl)-9-isobutyl-8,11-dioxa-17,20-diaza-spiro[5.15]henicos-14-ene-7,10,16,19-tetraone 
• 223763-97-1 (E)-(9S,12S,18R)-18-(3-Chloro-4-methoxy-benzyl)-9-isobutyl-12-((E)-(R)-1-methyl-3-phenyl-allyl)-8,11-dioxa-17,20-diaza-spiro[5.15]henicos-14-ene-7,10,16,19-tetraone 

Relevant academic research and scientific papers

Synthesis and biological evaluation of cryptophycin analogs with substitution at C-6 (fragment C region)

Analogs of the antitumor agents cryptophycins 1 and 8 with dialkyl substitution at C-6 (fragment C) were synthesized and evaluated for in vitro cytotoxicity against human leukemia cells (CCRF-CEM). The activity of these analogs decreased as the size of the substituents at C-6 increased. The C-6 spirocylopropyl compound (2g) was highly potent in vitro and showed excellent antitumor activity in animal models.